BioMimetic Ramps Up R&D For Synthetic Bone Products
This article was originally published in The Gray Sheet
Executive Summary
Combination products firm BioMimetic expects rapid enrollment this fall in a U.S. pivotal study of a product to facilitate fusions in the foot and ankle, CEO Samuel Lynch said during an Aug. 14 earnings call
You may also be interested in...
BioMimetic Aims To Complete Bone Graft Study Enrollment By Year-End
BioMimetic Therapeutics is hoping enrollment in an ongoing pivotal trial for its Augment Bone Graft will be complete by year-end despite a recent slowdown in registration
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.